BLIS Technologies Limited (Blis Technologies Limited Ordin) Aktie

BLIS Technologies Limited, together with its subsidiaries, develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity in New Zealand, Asia Pacific, Europe Middle East and Africa, and North America. The company offers BLIS K12, an oral probiotic supplement to support ear, nose, and throat health, as well as for enhancing immunity and bad breath; BLIS M18, an oral probiotic to support teeth and gums health; and BLIS Q24, a probiotic supplement to balance the skin microbiome, restoring the health, clarity, and radiance. It provides its products in the ENT, immune, dental, and skin areas. BLIS Technologies Limited was incorporated in 2000 and is based in Dunedin, New Zealand.